RYTM
RHYTHM PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$91.89
+6.31%Next report
Analyst consensus
- Next report date
- Feb 25, 2027
- EPS estimate
- -$0.63
- Revenue estimate
- $108.0M
Latest reported
- Last report date
- Nov 3, 2026
- EPS actual
- -$0.61
- EPS estimate
- -$0.71
- Revenue actual
- $92.1M
- Revenue estimate
- $85.6M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +8.7%
- Revenue beats (12Q)
- 9
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $139
- PT range
- $114 – $160
- Analysts
- 9
8 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 3, 2026 | -$0.71 | -$0.61 | Beat 14.05% | $92.1M |
| Aug 4, 2026 | -$0.81 | -$0.73 | Beat 9.57% | $71.3M |
| May 5, 2026 | -$0.86 | -$0.83 | Beat 3.49% | $60.1M |
| Feb 26, 2026 | -$0.79 | -$0.73 | Beat 7.56% | $57.3M |
| Feb 26, 2025 | -$0.69 | -$0.72 | Miss -4.35% | $41.8M |
| Feb 22, 2024 | -$0.70 | -$0.70 | In line | $24.2M |
| May 2, 2023 | -$0.71 | -$0.92 | Miss -29.58% | $11.5M |
| Mar 1, 2023 | -$0.82 | -$0.75 | Beat 8.54% | $8.8M |
| Aug 2, 2022 | -$0.79 | -$0.89 | Miss -12.66% | $9.1M |
| May 3, 2022 | -$0.98 | -$1.05 | Miss -7.14% | $1.5M |
| Mar 1, 2022 | -$1.00 | -$0.85 | Beat 15.00% | $1.8M |
| Nov 2, 2021 | -$0.84 | -$0.70 | Beat 16.67% | $1.0M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 25, 2027